Article

4-Aryleyelohexylaianine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV

Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.
Bioorganic & Medicinal Chemistry Letters (Impact Factor: 2.33). 12/2007; 17(21):5806-11. DOI: 10.1016/j.bmcl.2007.08.049
Source: PubMed

ABSTRACT A novel series of 4-arylcyclohexylalanine DPP-4 inhibitors was synthesized and tested for inhibitory activity as well as selectivity over the related proline-specific enzymes DPP-8 and DPP-9. Optimization of this series led to 28 (DPP-4 IC50 = 4.8 nM), which showed an excellent pharmacokinetic profile across several preclinical species. Evaluation of 28 in an oral glucose tolerance test demonstrated that this compound effectively reduced glucose excursion in lean mice. (c) 2007 Elsevier Ltd. All rights reserved.

0 Followers
 · 
121 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Emerging as an epidemic of the 21st century type 2 diabetes has become a major health problem throughout the globe. The number of deaths attributable to diabetes reflects the insufficient glycemic control achieved with the treatments used in recent past. DPP-4 inhibitors have been investigated as a new therapy with novel mechanisms of action and improved tolerability. DPP-4, a protease that specifically cleaves dipeptides from proteins and oligopeptides after a penultimate N-terminal proline or alanine, is involved in the degradation of a number of neuropeptides, peptide hormones and cytokines, including the incretins GLP-1 and GIP. As soon as released from the gut in response to food intake, GLP-1 and GIP exert a potent glucose-dependent insulinotropic action, thereby playing a key role in the maintenance of post-meal glycemic control. Consequently, inhibiting DPP-4 prolongs the action of GLP-1 and GIP, which in turn improves glucose homeostasis with a low risk of hypoglycemia and potential for disease modification. Indeed, clinical trials involving diabetic patients have shown improved glucose control by administering DPP-4 inhibitors, thus demonstrating the benefit of this promising new class of antidiabetics. Intense research activities in this area have resulted in the launch of sitagliptin and vildagliptin (in Europe only) and the advancement of a few others into preregistration/phase 3, for example, saxagliptin, alogliptin and ABT-279. Achieving desired selectivity for DPP-4 over other related peptidases such as DPP-8 and DPP-9 (inhibition of which was linked to toxicity in animal studies) and long-acting potential for maximal efficacy (particularly in more severe diabetic patients) were the major challenges. Whether these goals are achieved with the present series of inhibitors in the advanced stages of clinical development is yet to be confirmed. Nevertheless, treatment of this metabolic disorder especially in the early stages of the disease via DPP-4 inhibition has been recognized as a validated principle and a large number of inhibitors are presently in various stage of pre-clinical/clinical development. Sitagliptin is a new weapon in the arsenal of oral antihyperglycemic agents. This review will focus on the journey of drug discovery of DPP-4 inhibitors for oral delivery covering a brief scientific background and medicinal chemistry approaches along with the status of advanced clinical candidates.
    Bioorganic & medicinal chemistry 02/2009; 17(5):1783-802. DOI:10.1016/j.bmc.2009.01.061 · 2.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interacting fragments (IFs) derived from protein-ligand complex crystal structures have previously been utilized to complement conventional two-dimensional (2D) similarity searching. In many instances, the (indirect) incorporation of three-dimensional (3D) interaction information through the use of IFs has further improved the search performance of fingerprints of unmodified ligands. However, for a number of targets, changes in the relative performance of conventional fingerprints and IF-based representations have also been observed, and reasons for these effects have thus far remained elusive. Herein, we analyze target-ligand systems that display different similarity search phenotypes. We study protein-ligand interactions and the resulting IF information at the molecular level of detail in order to better understand systematic differences in the search performance of unmodified ligands and IFs. The results show that the degree of conservation of IFs isolated from multiple crystallographic ligands is a major determinant of similarity search performance, regardless of whether IFs consist of coherent substructures or disjoint fragments. Conserved IFs focus similarity search calculations on 2D pharmacophore elements, as revealed by 3D interaction analysis. This leads to increased hit rates compared to unmodified reference ligand representations and to the recognition of smaller and less complex, yet structurally diverse hits. On the basis of these findings, one can predict for which targets the inclusion of IF information will likely result in improved 2D similarity search performance.
    Journal of Chemical Information and Modeling 05/2010; 50(6):1042-52. DOI:10.1021/ci1001197 · 4.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dipeptidyl peptidase IV (DPP4) is an important target for the treatment of type II diabetes mellitus. Inhibition of DPP4 will improve glycemic control in such patients by preventing the rapid breakdown and thereby prolonging the physiological actions of incretin hormones. Known DPP4 inhibitors (including marketed drugs and those drug candidates) appear to share similar structural features: the cyanopyrrolidine moieties, the xanthenes/pyrimidine parts and amino-like linkages. In this study, a multi-step virtual screening strategy including both rigid and flexible docking was employed to search for novel structures with DPP4 inhibition. From SPECS database, consisting of over 190,000 commercially available compounds, 99 virtual hits were picked up and 15 of them were eventually identified to have DPP4 inhibitory activities at 5 ~ 50 μM. Diverse structures of our compounds were out of usual structural categories. Hence a pharmacophore model was built to further explore their common binding features on the enzyme. The results provided a new pathway for the discovery of DPP4 inhibitors and would be helpful for further optimization of DPP4 inhibitors.
    Journal of Molecular Modeling 03/2012; 18(9):4033-42. DOI:10.1007/s00894-012-1394-3 · 1.87 Impact Factor